Sirtex Medical
32
6
8
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.8%
6 terminated/withdrawn out of 32 trials
71.4%
-15.2% vs industry average
9%
3 trials in Phase 3/4
47%
7 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (32)
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
Role: collaborator
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Role: collaborator
A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis.
Role: lead
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
Role: collaborator
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Role: collaborator
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
Role: lead
RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study
Role: collaborator
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
Role: collaborator
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Role: lead
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
Role: lead
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
Role: lead
Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy
Role: collaborator
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
Role: collaborator
Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
Role: collaborator
A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver
Role: collaborator
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
Role: lead
A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC
Role: collaborator
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Role: lead
Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer
Role: collaborator
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
Role: collaborator